Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.
Angew Chem Int Ed Engl · 2015
Last updated 2026-05-28Researchers created a new antibody-based drug by attaching a GLP-1 receptor agonist (Exendin-4) to an engineered antibody. In lab tests, this fusion protein was more effective at activating GLP-1 receptors than Exendin-4 alone. In mice, the drug had a long-lasting effect, with a plasma half-life of about four days and sustained blood sugar control for over a week.
AI summary of the abstract below.
| Journal | Angew Chem Int Ed Engl, 2015 |
|---|---|
| Citations | 27 |
| Relative citation ratio | 0.92 |
| NIH percentile | 48 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Bovine antibody BLV1H12 possesses a unique "stalk-knob" architecture in its ultralong heavy chain CDR3, allowing substitutions of the "knob" domain with protein agonists to generate functional antibody chimeras. We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibody by first introducing a coiled-coil "stalk" into CDR3H of the antibody herceptin. Exendin-4 (Ex-4), a GLP-1 receptor agonist, was then fused to the engineered stalk with flexible linkers, and a Factor Xa cleavage site was inserted immediately in front of Ex-4 to allow release of the N-terminus of the fused peptide. The resulting clipped herceptin-Ex-4 fusion protein is more potent in vitro in activating GLP-1 receptors than the Ex-4 peptide. The clipped herceptin-Ex-4 has an extended plasma half-life of approximately four days and sustained control of blood glucose levels for more than a week in mice. This work provides a novel approach to the development of human or humanized agonist antibodies as therapeutics.
Verbatim abstract via PubMed 25556336 ↗